University Hospital of Heidelberg, Radiation Oncology 69120 Heidelberg (Baden-Württemberg) GermanyRekrutierend» Google-Maps Ansprechpartner: Jürgen Debus, Prof. Dr. Phone: +49-6221-56 Phone (ext.): 8202 E-Mail: juergen.debus@med.uni-heidelberg.de
1. incidence and grade of vaginal fibrosis (Time Frame - Up to 12 months after start of (chemo)radiotherapy): during and after radiotherapy, clinical symptoms are assessed and graded
Secondary outcome:
1. clinical symptoms and toxicity according to the CTC AE version 5.0. criteria (Time Frame - weekly during radiotherapy, at each follow-up visit): during and after radiotherapy, clinical symptoms are assessed and graded according to the CTC AE v5.0 criteria
2. clinical feasibility of daily use of a special tampon (Time Frame - continously during radiotherapy): daily assessment of the clinical feasibility of daily use of a special tampon
3. assessment of the compliance for the use of a vaginal dilatator (Time Frame - continously at every follow-up visit): patients will be instructed to use a vaginal dilator 3 times a week, at each follow-up visit patients are asked about the frequency of vaginal dilator use
4. assessment of quality of life (Time Frame - baseline, 6-8 weeks after and 6/12 months after finishing radiotherapy): EORTC-QLQ30/-ANL27 questionnaires are used to assess quality of life
Experimental: Tampon with extended vaginal dilatation Patients in arm A will use a special tampon with extended vaginal dilatation during radiotherapy
Active Comparator: Commercially available tampon Patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
